Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Equity (2020 - 2026)

Nurix Therapeutics (NRIX) has disclosed Return on Equity for 7 consecutive years, with 0.58% as the latest value for Q1 2026.

  • Quarterly Return on Equity fell 17.0% to 0.58% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.58% through Feb 2026, down 17.0% year-over-year, with the annual reading at 0.5% for FY2025, 4.0% up from the prior year.
  • Return on Equity for Q1 2026 was 0.58% at Nurix Therapeutics, roughly flat from 0.58% in the prior quarter.
  • The five-year high for Return on Equity was 0.41% in Q1 2025, with the low at 0.78% in Q1 2024.
  • Average Return on Equity over 5 years is 0.56%, with a median of 0.58% recorded in 2026.
  • The sharpest move saw Return on Equity dropped -25bps in 2022, then soared 37bps in 2025.
  • Over 5 years, Return on Equity stood at 0.56% in 2022, then dropped by -19bps to 0.66% in 2023, then skyrocketed by 35bps to 0.43% in 2024, then crashed by -36bps to 0.58% in 2025, then grew by 0bps to 0.58% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.58%, 0.58%, and 0.6% for Q1 2026, Q4 2025, and Q3 2025 respectively.